A5102731193- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Breast Implant and Reconstruction
- Cancer Treatment and Pharmacology
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- Lymphoma Diagnosis and Treatment
- Complementary and Alternative Medicine Studies
- Global Cancer Incidence and Screening
- BRCA gene mutations in cancer
- Reconstructive Surgery and Microvascular Techniques
- Herbal Medicine Research Studies
- Phytochemistry Medicinal Plant Applications
- Viral-associated cancers and disorders
- Digital Radiography and Breast Imaging
- Patient-Provider Communication in Healthcare
- Colorectal Cancer Screening and Detection
- Ovarian cancer diagnosis and treatment
- Lymphatic System and Diseases
- Clinical practice guidelines implementation
- Lung Cancer Treatments and Mutations
- Salivary Gland Tumors Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Genetic factors in colorectal cancer
Centre for the Observation and Modelling of Earthquakes, Volcanoes and Tectonics
2024
McGill University
2013-2024
McGill University Health Centre
2013-2024
Legacy Health
2011-2024
Jewish General Hospital
2013-2024
University of Southern California
2023
Northwestern University
2023
Good Samaritan Medical Center
2021
Legacy Good Samaritan Medical Center
2005-2020
Good Samaritan Hospital
2015
In the last half of century, advances in systemic therapy cancer, including chemotherapy, hormonal therapy, targeted and immunotherapy have been responsible for improvements cancer related mortality developed countries even as population continues to age. Although such advancements yet benefit all types, therapies led an improvement overall survival both adjuvant metastatic setting many cancers. With pressure make available soon possible, side-effects therapies, particular long-term are not...
Abstract Background The impact of length time to surgery (TTS) on oncologic outcomes following neoadjuvant chemotherapy (NAC) in breast cancer patients is unclear. We investigated the relationship between TTS residual burden (RCB) score and outcomes. Methods Patients with receiving NAC from 2011 2017 were identified. association recurrence‐free survival (RFS), overall disease‐specific (OS, DSS), RCB was examined Kaplan–Meier Cox proportional hazards analysis, adjusting for relevant...
511 Background: The MammaPrint (MP) risk of distant recurrence signature identifies hormone receptor-positive (HR+), HER2-negative early-stage breast cancer (EBC) patients (pts) with increased or decreased chemosensitivity and chemotherapy (CT) benefit. MINDACT trial demonstrated excellent outcomes for MP Low Risk tumors without CT, previous studies show High exhibit higher sensitivity benefit CT. There remains an unmet clinical need identifying biomarkers to inform specific regimen planning...
In this retrospective cohort study of 174 consecutive, newly diagnosed cases diffuse large B-cell lymphoma (DLBCL), clinical and pathological variables, treatment, response survival were compared for patients aged 80 over (n = 40) to those under 80. Eastern Cooperative Oncology Group (ECOG) status International Prognostic Index (IPI) significantly worse among older patients. Standard treatment was given only 32.5% versus 86.6% younger patients, 65% the elderly did not receive standard...
Abstract Background Patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer are treated trastuzumab‐based neoadjuvant therapy (NAT); some patients residual disease post‐NAT show loss of HER2 amplification and has been inconsistently associated oncologic outcomes. Methods We queried our multi‐institutional registry for women HER2‐positive undergoing NAT from 2011 to 2018. Clinicopathologic, treatment‐related, outcomes data were collected. Kaplan–Meier Cox...